Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT in Acutely Psychotic Adults with Schizophrenia (EMERGENT-2)
NCT04659161Phase 3Completed
- Sponsor
- Karuna Therapeutics
- Start
- Dec 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing KarXT with Placebo (2 arms). Primary endpoint: Positive and Negative Syndrome Scale Total Score at 5 weeks. Started Dec 2020; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04659161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659161.